| Literature DB >> 31784822 |
Gita Rajan1,2, Gunnar Ljunggren3,4, Per Wändell3, Lars Wahlström5, Carl Göran Svedin6, Axel C Carlsson3.
Abstract
Victims of sexual abuse have more co-morbidities than other persons in the same age and the most affected group are adolescent girls. Little is known about how this is reflected in health care consumption patterns prior to the registered diagnosis. The aim of this investigation was to study health care consumption patterns among girls, 12-17 years old, 1 and 2 years prior to their diagnoses of sexual abuse. Through the Stockholm Region administrative database (VAL), data of co-morbidities, number of health care visits, and prescribed drugs were collected for cases (girls age 12-17 with diagnoses of sexual abuse, n = 519) and controls matched for age and socio-economic status (n = 4920) between 2011-2018. Health care consumption and co-morbidities were significantly higher for the cases compared to controls, with a rise 1 year before the diagnoses: the total number of health care visits (including no shows) 1 year prior to the first recording of the diagnosis was 20.4 (18.1-22.7) for the cases and 6.2 (5.8-6.6) for the controls. The most frequent visits 1 year prior to the diagnosis were to outdoor clinics, with a mean value of 19.1 (16.9-21.3) visits for the cases and 5.7 (5.3-6.1) for the controls, followed by psychiatric clinics with a mean value of 12.7 (10.6-14.8) visits for the cases and 2.0 (1.7-2.3) visits for the controls. The least visited health care clinic 1 year prior to the diagnosis was the emergency ward with a mean value of 1.3 (1.1-1.5) visits for the cases and 0.5 (0.4-0.5) visits for the controls. The most common psychiatric co-morbidities registered among the cases during the first year before the diagnosis of sexual abuse were stress, suicide attempt, and psychosis. Neuroleptics, sleeping pills, antidepressants, and tranquilizers were more frequently dispensed in cases than in controls. Similar patterns were found 2 years prior to the diagnosis. We encourage clinicians to actively ask for exposure of sexual abuse in girls with high health care consumption, making early detection and treatment of sexual abuse available as soon as possible.Entities:
Keywords: Administrative databases; Comorbidity; Epidemiology; Medication; Sexual abuse
Mesh:
Year: 2019 PMID: 31784822 PMCID: PMC7501119 DOI: 10.1007/s00787-019-01445-y
Source DB: PubMed Journal: Eur Child Adolesc Psychiatry ISSN: 1018-8827 Impact factor: 4.785
Number of health care visits in adolescent girls with a diagnosis of sexual abuse and their matched controls 1 (1–365 days) and 2 years (366–730 days) prior to the first diagnosis of sexual abuse (2011–2018)
| Clinics visited | Cases 1 year prior to diagnosis | Controls 1 year prior to diagnosis | Cases 2 years prior to diagnosis | Controls 2 years prior to diagnosis |
|---|---|---|---|---|
| All clinics visits | 20.12 (17.91–22.34) | 5.39 (5.09–5.69) | 10.71 (9.19–12.23) | 4.43 (4.14–4.71) |
| Emergency clinic visits | 1.28 (1.08–1.48) | 0.40 (0.37–0.43) | 0.83 (0.68–0.98) | 0.38 (0.35–0.40) |
| Outdoor clinic visits | 18.85 (16.72–20.97) | 4.99 (4.70–5.28) | 9.89 (8.44–11.33) | 4.05 (3.78–4.33) |
| Psychiatry clinic | 12.42 (10.36–14.49) | 1.74 (1.52–1.96) | 5.69 (4.38–7.00) | 1.24 (1.05–1.43) |
| Primary health care | 3.64 (3.16–4.10) | 2.22 (2.07–2.37) | 2.99 (2.64–3.34) | 2.06 (1.92–2.20) |
| Other specialist clinic | 2.04 (1.87–2.21) | 0.49 (0.45–0.54) | 0.60 (0.45–0.74) | 0.38 (0.35–0.42) |
| Pediatric clinic | 2.02 (1.73–2.31) | 0.94 (0.87–1.00) | 1.43 (1.19–1.68) | 0.75 (0.69–0.81) |
| “No show” at planned visits | 1.41 (1.16–1.66) | 0.29 (0.25–0.32) | 0.75 (0.58–0.92) | 0.22 (0.18–0.25) |
Numbers of visits to different health care professional groups for cases and controls 1 (1–365 days) and 2 years (366–730 days) prior to the first diagnosis of sexual abuse (2011–2018)
| Professionals responsible for the visit | Cases 1 year prior to diagnosis | Controls 1 year prior to diagnosis | Cases 2 years prior to diagnosis | Controls 2 years prior to diagnosis |
|---|---|---|---|---|
| Psychologist, therapist, social worker | 8.87 (7.37–10.36) | 1.34 (1.18–1.5) | 3.83 (2.93–4.74) | 0.88 (0.75–1.01) |
| Physician | 6.35 (5.78–6.92) | 2.34 (2.25–2.44) | 3.98 (3.39–4.57) | 2.15 (2.05–2.25) |
| Other | 4.91 (4.19–5.63) | 1.71 (1.56–1.86) | 2.90 (2.43–3.37) | 1.4 (1.25–1.55) |
Odds ratios for relevant co-morbidities in sexually abused girls compared to non-abused controls 1 (1–365 days) and 2 years (366–730 days) prior to the first recorded diagnosis of sexual abuse (2011–2018)
| Diagnoses | OR 1 year prior to diagnosis | OR 2 years prior to diagnosis |
|---|---|---|
| Psychosis (F20, F23, F25, F28, F29) | 19.03 (1.72–210.21) | 3.17 (0.33–30.49) |
| Suicide attempt (× 6) | 15.51 (7.89–30.51) | 5.91 (2.44–14.33) |
| Stress (F43) | 12.37 (7.73–19.79) | 7.55 (3.73–15.27) |
| All substance abuse (F10–F19) | 6.29 (3.70–10.70) | 3.99 (2.03–7.88) |
| Alcohol abuse (F10) | 6.07 (3.16–11.65) | 3.05 (1.30–7.17) |
| Depression (F32, F33) | 5.8 (3.87–8.69) | 2.96 (1.54–5.70) |
| Anxiety (F 40, F41) | 5.16 (3.70–7.18) | 4.97 (3.18–7.78) |
| Autism (F.84) | 4.25 (2.49–7.24) | 3.13 (1.62–6.03) |
| ADHD (F90) | 3.1 (2.22–4.46) | 3.02 (2.01–4.53) |
| Pain (R10, R51, R52, G44, M79) | 1.80 (1.43–2.27) | 1.53 (1.19–1.96) |
| Eating disorders (F50) | 1.70 (0.65–4.42) | 2.65 (0.98–7.17) |
| Bipolar disorder (F30, F31) | 1.59 (0.19–13.17) | > 0.001 |
| Borderline (F60) | − | − |
Odds ratios for collected prescriptions of relevant pharmacotherapies in sexually abused girls, 1 (1–365 days) and 2 years (366–730 days) prior to the first registered diagnosis of sexual abuse
| Pharmaceutical drug type | Odds ratios 1 year prior to diagnosis | Odds ratios 2 years prior to diagnosis |
|---|---|---|
| Tranquilizers (R06AD02, N05BB) | 8.91 (6.55–12.14) | 5.14 (3.23–8.19) |
| NRLP (N05A) | 8.00 (3.92–16.32) | 4.1 (1.57–10.72 |
| Propiomazine (N05CM06) | 7.42 (3.58–15.36) | 3.68 (1.31–10.35) |
| Antidepressant drugs (N06A) | 7.17 (5.36–9.60) | 4.40 (2.94–6.58) |
| Melatonin (N05CH01) | 4.62 (3.35–6.37) | 2.58 (1.60–4.20) |
| Hypnotics (N05CF) | 3.80 (0.74–19.66) | − |
| Stimulants (N06BA) | 3.36 (2.40–4.71) | 3.63 (2.46–5.34) |
| Benzodiazepines (N05CD, N05BA) | 3.02 (1.20–7.59) | 1.19 (0.27–5.17) |